HOME / NEWS
Newsroom
Facility expansions, platform launches, partnerships and commercial milestones from across Tandemab Bio.
The new stainless-steel suite at our Ardvale, NC site roughly doubles Tandemab's commercial drug-substance capacity, adding two 25,000 L production trains with integrated continuous downstream recovery. The expansion supports late-stage and commercial partners scaling out of our pilot plant.
READ MORE →The latest release of our strain-and-process development platform expands parallel micro-fermentation to 48 channels and adds automated refold screening. Internal benchmarking shows median construct-to-feasibility timelines falling from fourteen to eight weeks across recent recombinant-protein programs.
READ MORE →Under the agreement, Tandemab will provide process development and clinical-through-commercial drug substance for a recombinant vaccine antigen expressed in Pichia pastoris. The program runs across our Granton Point and Vendel sites with a shared on-time-launch plan.
READ MORE →Our Vendel, Netherlands facility completed a routine GMP inspection by European authorities with no critical or major findings. The result extends Tandemab's unbroken record of inspection readiness across all three manufacturing sites.
READ MORE →Tandemab's strain engineering team has validated an engineered, protease-deficient bacterial host that improves intact-product yield for sensitive novel scaffolds. The strain is now available to partner programs through the FoldForge platform.
READ MORE →A Bacillus subtilis-expressed enzyme that Tandemab carried from strain development through commercial manufacturing has reached market launch on the original timeline, marking our 540th completed program milestone.
READ MORE →Media & press
For media requests or to discuss a partnership, reach our communications team directly.